{
    "eid": "2-s2.0-85124178091",
    "title": "SARS-CoV-2 variants: A continuing threat to global health",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Balamurugan Shanmugaraj",
        "Narach Khorattanakulchai",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 3,
    "ref-count": 10,
    "ref-list": [
        "Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost",
        "Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant",
        "The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron",
        "SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection",
        "COVID-19-associated mucormycosis and treatments",
        "SARS-CoV-2 Omicron Variant: Could it be another threat?"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "126563806",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126563806",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Vaccine Institute, Thailand and Baiya Phytopharm Co., Ltd.",
        "Chulalongkorn University"
    ]
}